Literature DB >> 12737510

Central and peripheral vision loss associated with nefazodone usage.

Chi Luu1, Patricia Kiely, David Crewther, Lionel Kowal, Sheila Crewther.   

Abstract

A 35-year-old woman who reported persistent significant vision loss for 3 years after taking the antidepressant nefazodone was referred for electrophysiological assessment of vision. The vision changes included reduced acuities, reduced colour vision and visual field constriction in both eyes and were thought to be associated with the use of nefazodone for 6 - 8 weeks, 3 years earlier. Multifocal electroretinograms and visual evoked potentials were recorded using the Visual Evoked Response Imaging System (VERIS) to investigate the nature and site of the neural deficit. The summed retinal response showed a normal a- and b-wave latency and amplitude, however, the retinal topographic mfERGs showed a severe depression of the macular response in both eyes. The cortical topographic multifocal VEP mapping also showed a central depression in the right eye compared with the left. Two-frame motion and pattern custom mfVEP were also measured to assess different forms of cortical processing and especially of motion as nefazodone has previously been associated with image persistence with moving stimuli. The responses to two frame-motion showed signs of abnormality. Thus these results suggest that the primary locus of neural damage is retinal and is likely to have resulted from neurotoxicity. Other competing hypotheses such as hysterical blindness must be ruled out.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12737510     DOI: 10.1023/a:1022951526424

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  11 in total

1.  Visual "trails" with nefazodone treatment.

Authors:  R P Kraus
Journal:  Am J Psychiatry       Date:  1996-10       Impact factor: 18.112

2.  Temporal analysis of the topographic ERG: chromatic versus achromatic stimulation.

Authors:  A Klistorner; D P Crewther; S G Crewther
Journal:  Vision Res       Date:  1998-04       Impact factor: 1.886

3.  Separate magnocellular and parvocellular contributions from temporal analysis of the multifocal VEP.

Authors:  A Klistorner; D P Crewther; S G Crewther
Journal:  Vision Res       Date:  1997-08       Impact factor: 1.886

4.  Nefazodone and visual side effects.

Authors:  K Schwartz
Journal:  Am J Psychiatry       Date:  1997-07       Impact factor: 18.112

5.  Trazodone-induced palinopsia.

Authors:  M S Hughes; S Lessell
Journal:  Arch Ophthalmol       Date:  1990-03

Review 6.  Tolerability and safety: essentials in antidepressant pharmacotherapy.

Authors:  M H Lader
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

7.  Akinetopsia from nefazodone toxicity.

Authors:  J C Horton; J D Trobe
Journal:  Am J Ophthalmol       Date:  1999-10       Impact factor: 5.258

Review 8.  Nefazodone: a new antidepressant.

Authors:  V L Ellingrod; P J Perry
Journal:  Am J Health Syst Pharm       Date:  1995-12-15       Impact factor: 2.637

9.  The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies.

Authors:  M J Owens; J R Ieni; D L Knight; K Winders; C B Nemeroff
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

10.  Interaction between tacrolimus and nefazodone in a stable renal transplant recipient.

Authors:  A J Olyaei; A M deMattos; D J Norman; W M Bennett
Journal:  Pharmacotherapy       Date:  1998 Nov-Dec       Impact factor: 4.705

View more
  2 in total

1.  Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users.

Authors:  M Rizzo; C T J Lamers; C G Sauer; J G Ramaekers; A Bechara; G J Andersen
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

2.  Inhibitors of 7-Dehydrocholesterol Reductase: Screening of a Collection of Pharmacologically Active Compounds in Neuro2a Cells.

Authors:  Hye-Young H Kim; Zeljka Korade; Keri A Tallman; Wei Liu; C David Weaver; Karoly Mirnics; Ned A Porter
Journal:  Chem Res Toxicol       Date:  2016-04-28       Impact factor: 3.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.